证券代码：002422 证券简称：科伦药业 公告编号：2023-104 债券代码：127058 债券简称：科伦转债 四川科伦药业股份有限公司 关于主要产品A140注射液（西妥昔单抗注射液）上市申请获NMPA受 理的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）近日获悉， 公司控股子公司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"） 开发的A140注射液（西妥昔单抗注射液，商品名称：达泰莱）的上市申请获得国 家药品监督管理局药品审评中心受理。现将相关情况公告如下： 一、药品基本情况 1.药品信息 药物名称：西妥昔单抗注射液 商品名称：达泰莱 剂 型：注射剂 规 格：100mg（50ml）/瓶 申请事项：境内生产药品注册上市许可 受 理 号：CXSS2300075 拟定适应症： 本品用于治疗 RAS 基因野生型的转移性结直肠癌：与 FOLFOX 或 FOLFIRI 方案联合用于一线治疗；与伊立替康联合用于经含伊立替康治疗失败后的患者。 1 本品用于治疗头颈部鳞状细胞癌：与铂类和氟尿嘧啶化疗联合 ...

Sales Performance - The company's infusion revenue for the first half of 2023 reached approximately 50.27 billion RMB, a year-on-year increase of 14% [2] - Non-infusion revenue was around 18 billion RMB, with traditional drugs contributing 10.2 billion RMB [2] - The new generic drug revenue was 8.1 billion RMB, reflecting a slight decline due to price reductions from centralized procurement [2] Research and Development - R&D expenses for the first half of 2023 totaled 4.9 billion RMB, with a focus on key pipelines and competitive projects [2] - The company expects to maintain approximately 30 new approvals annually in the coming years based on current application inventory and project progress [3] Market Strategy - The company is expanding its product pipeline in critical areas such as infectious diseases, central nervous system, and anesthesia [3] - The closed infusion system's market share is projected to increase by 2.5 billion bags in 2023, with ongoing market development efforts [3] Product Development - The dual-chamber bag production capacity is expected to ramp up by the end of 2023, with new products entering the National Medical Insurance negotiation process [4] - The company plans to introduce over 20 new products, including various antibiotics, in the near future [4] Competitive Landscape - The male health product segment has seen a sales volume increase of over 30%, despite a decline in sales value due to intensified competition [3] - The ninth batch of centralized procurement includes 44 generic names, with the company qualifying for 4 products and potentially 4-6 more under review [3]

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a total revenue of CNY 3.5 billion, representing a year-on-year growth of 15%[2]. - The net profit attributable to shareholders reached CNY 600 million, an increase of 20% compared to the same period last year[2]. - The company reported a revenue of 1.5 billion CNY for the first half of 2023, representing a year-on-year increase of 12%[7]. - The net profit attributable to shareholders reached 300 million CNY, up 15% compared to the same period last year[7]. - The company's operating revenue for the first half of 2023 reached ¥10,733,926,609, representing a 17.64% increase compared to ¥9,124,621,759 in the same period last year[12]. - Net profit attributable to shareholders was ¥1,402,202,255, a significant increase of 61.53% from ¥868,078,939 in the previous year[12]. - The company reported a significant increase in international business revenue, which rose by 145.83% to ¥1,630,357,606, representing 15.19% of total revenue[74]. - The company’s financial expenses decreased by 30.83% to ¥165,796,704, attributed to a reduction in interest-bearing debt and an increase in interest income[72]. Market Expansion and Product Development - User data indicates a growth in the customer base, with an increase of 25% in active users, totaling 1.5 million[2]. - The company has outlined a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 15%[2]. - New product launches are expected to contribute an additional CNY 500 million in revenue by the end of the year[2]. - Market expansion plans include entering two new provinces, aiming for a 5% market share in these regions within the next year[2]. - The company is investing heavily in R&D, with an allocation of CNY 200 million for new technology development in the pharmaceutical sector[2]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[7]. - The company plans to enhance its digital marketing strategies to further engage with customers and increase brand awareness[7]. Research and Development - The company is investing 200 million CNY in R&D for new drug development, focusing on oncology and chronic diseases[7]. - The company has developed a total of 634 varieties of pharmaceutical products, including 132 infusion products and 420 other dosage forms[16]. - The company has initiated over 400 major drug development projects across various disease areas since 2017, with 152 products approved[26]. - The company is recognized as a "Manufacturing Industry Single Champion Demonstration Enterprise" by the Ministry of Industry and Information Technology, reflecting its leadership in the infusion product sector[24]. - The company has established six national-level innovation platforms, including a national engineering research center for large-volume injectables[26]. Environmental Management - The company is committed to environmental risk management by implementing advanced pollution control technologies and emergency response plans[102]. - The company has established a comprehensive environmental management system to monitor and control pollution sources effectively[115]. - The company has implemented measures to ensure that all emissions, including ammonia nitrogen and carbon monoxide, remain below the specified limits[116]. - The company achieved a chemical oxygen demand (COD) discharge of 90.60 mg/L at the wastewater treatment station, which is below the agreed discharge limit of 1.8 tons per year[117]. - The company has constructed multiple air pollution control systems, including a new system for VOCs with a capacity of 1,500 m³/h, which is currently in intermittent operation[121]. Shareholder and Equity Information - No cash dividends will be distributed to shareholders for this period, as the company focuses on reinvestment strategies[1]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[107]. - The total number of shares increased from 1,422,247,156 to 1,475,047,235, reflecting a net increase of 52,800,079 shares[153]. - The company repurchased a total of 7,272,164 shares at a maximum price of 20.05 RMB per share and a minimum price of 16.08 RMB per share, with a total expenditure of 131,686,424.56 RMB[155]. - The total number of ordinary shareholders at the end of the reporting period was 33,912[158]. Risk Management - The company acknowledges potential risks including market fluctuations and regulatory changes, which may impact future performance[1]. - The company faces industry policy risks due to stricter regulations in the pharmaceutical sector, which may require strategic adjustments[100]. - Market risks include rising production costs and ongoing price pressures from healthcare policies, prompting the company to optimize production processes and expand procurement channels[101]. - The company has implemented risk control measures for foreign exchange hedging, including the establishment of a management system and regular monitoring of market conditions[90]. Financial Strategy - The company has engaged in foreign exchange forward contracts with various banks, with initial investments totaling CNY 1,318.13 million, CNY 1,314.86 million, and CNY 1,311.53 million, showing a reported profit of CNY 42.56 million, CNY 10.64 million, and CNY 5.30 million respectively[88]. - The company has a total of CNY 3,944.52 million in derivative positions, with a market value change resulting in a loss of CNY 547.23 million during the reporting period[89]. - The company has consistently engaged in structured deposits, reflecting a strategy to optimize cash management and yield[147][148]. - The company is focusing on maintaining a balance between risk and return through its structured deposit offerings[147][148].

| | | 四川科伦药业股份有限公司 关于公司控股股东部分股份质押及解除质押的公告 二、股东股份质押的基本情况 | | 是否为控 | | 占其所 | 占公 | 是否为限 售股（如 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东姓 | 股股东或 | 本次质押 | | 司总 | | 为补 | 质押起始 | 质押到期 | | | | 名 | 第一大股 | （股） | 持股份 | 股本 | 是，注明 | 充质 | 日 | 日 | 质权人 | 质押用途 | | | 东及其一 | | 比例 | 比例 | 限售类 | 押 | | | | | | | 致行动人 | | | | 型） | | | | | | | 刘革新 | 是 | 12,000,000 | 3.17% | 0.81% | 是（高管 | 否 | 2023/08/ | 2024/08/ | 华泰证券 （上海）资 | 其他：个人 | | | | | | | 锁定股） | | 23 | 22 | 产管理有限 | 资金需求 | | | | | ...

| 非经营性资金占用 | 资金占用方 | 占用方与上市公司 | 上市公司核算 | 2023年期初占 | 2023年半年度占用累 | 2023年半年度占 用资金的利息(如 | 2023年半年度偿 | 2023年半年 期末占用资金 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | 的关联关系 | 的会计科目 | 用资金余额 | 计发生金额(不含利息) | | 还累计发生金额 | | 原因 | | | | | | | | | 有) | | 余额 | | | | 控股股东、实际控制人 及其附属企业 | 无 | 不适用 | 不适用 | - | - | - | - | - | 不适用 | 非经营性占用 | | 小计 | / | / | / | - | - | - | - | - | / | / | | 前控股股东、实际控制 人及其附属企业 | 无 | 不适用 | 不适用 | - | - | - | - | - | 不适用 | 非经营性占用 | | 小计 | / | / | / | - | ...

1 关于控股股东及其他关联方占用公司资金、公司对外担保情况的专 项说明和独立意见 四川科伦药业股份有限公司独立董事 2. 截至 2023 年 6 月 30 日，公司对控股子公司担保余额为 19.85 亿元，占公 司净资产的比例为 12.04%。除此之外，公司无其他对外担保事项、无逾期对外 担保、无涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。报告期 内，公司为控股子公司提供的担保符合相关法律法规及规范性文件要求，履行了 相应审批程序，不存在损害包括中小股东在内的全体股东及公司利益的情形。 根据《上市公司独立董事规则》、《上市公司治理准则》、《深圳证券交易所股 票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》、《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管 要求》及《公司章程》等有关规定，作为四川科伦药业股份有限公司（以下简称 "公司"）的独立董事，我们就公司 2023 年 1-6 月（以下简称"报告期"）控股股 东及其他关联方占用公司资金、公司对外担保情况进行了认真核查，并发表如下 专项说明和独立意见： 1. 报告期内公司不存在控股股东及其他 ...

| 证券代码：002422 | 证券简称：科伦药业 | 公告编号：2023-101 | | --- | --- | --- | | 债券代码：127058 | 债券简称：科伦转债 | | 四川科伦药业股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》和深圳证券交易所颁布的《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》等有关规定，四川科伦药业股份有 限公司（以下简称"公司"或"本公司"）董事会编制了截至 2023 年 6 月 30 日 募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于核准四川科伦药业股份有限公司公开发行 可转换公司债券的批复》（证监许可[2022]255 号）核准，公司于 2022 年 3 月 18 日公开发行 3,000.00 万张可转换公司债券，发行价格为每张 100 元，募集 ...

| 证券代码：002422 | 证券简称：科伦药业 公告编号：2023-102 | | --- | --- | | 债券代码：127058 | 债券简称：科伦转债 | 四川科伦药业股份有限公司 特此公告。 四川科伦药业股份有限公司（以下简称"公司"）董事会于近日收到黄新女 士提交的书面辞职报告，黄新女士因工作原因辞去公司证券事务代表职务，辞 职后黄新女士仍在公司担任其他职务。公司董事会对黄新女士担任公司证券事 务代表期间，为公司所做的贡献表示衷心的感谢。 公司于2023年8月28日召开第七届董事会第二十九次会议，审议通过了《关 于聘任公司证券事务代表的议案》，同意聘任王梦然先生担任公司证券事务代 表，协助董事会秘书履行各项职责，任期与第七届董事会成员任期一致。王梦 然先生任职资格符合《深圳证券交易所股票上市规则》等相关法律法规、规范 性文件的规定。王梦然先生的简历详见附件。 王梦然先生联系方式如下： 办公地址：四川省成都市青羊区百花西路36号 办公电话：028-82860678 关于证券事务代表辞职及聘任证券事务代表的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重 ...

四川科伦药业股份有限公司 第二条 本制度所称"理财"是指公司在国家有关法律、法规、规范性文件 及深圳证券交易所相关业务规则允许的情况下，在控制投资风险并履行投资决 策程序的前提下，以提高资金使用效率、增加现金资产收益为原则，以闲置的 自有资金通过银行及银行理财子公司、信托公司、资产管理公司、证券公司、 基金公司、保险公司等金融机构在确保安全性高、流动性好、低风险的基础上 进行资金运作及管理，以实现资金增值保值的行为。 公司以暂时闲置的募集资金进行理财业务的，根据公司《募集资金使用管 理制度》相关规定执行。 第三条 除本制度另有规定外，本制度适用于公司及全资子公司、控股子公 司（分拆上市的子公司除外）。公司全资子公司、控股子公司进行理财业务须 根据本制度报经公司审批，未经批准不得进行任何理财业务活动。分公司不得 开展理财业务。 第二章 基本原则 理财产品管理制度 第一章 总则 第一条 为规范四川科伦药业股份有限公司（以下简称"公司"）的理财交 易行为，有效控制风险，提高投资收益，维护公司及股东利益，依据《中华人 民共和国证券法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上 市公司自律监管指引第1号——主 ...

| 证券代码：002422 | 证券简称：科伦药业 | 公告编号：2023-099 | | --- | --- | --- | | 债券代码：127058 | 债券简称：科伦转债 | | 四川科伦药业股份有限公司 第七届监事会第十九次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）第七届监 事会第十九次会议通知于2023年8月17日以电话和电子邮件方式送达全体监事。 第七届监事会第十九次会议于2023年8月28日以现场结合通讯的方式召开，会议 应到监事3人，实到监事3人，其中监事万鹏先生现场出席会议，其余监事以通讯 方式出席会议。会议的召开符合《公司法》等法律、行政法规、部门规章、规范 性文件和《公司章程》的规定，作出的决议合法有效。 本次会议由监事会主席万鹏先生主持，与会监事就以下议案进行了审议、表 决，形成了如下决议： 一、以3票同意，0票反对，0票弃权，审议通过了《关于审议公司2023年半 年度报告及摘要的议案》 经审核，监事会认为董事会编制和审议公司2023年半年度报告的程序符合法 ...